- Home
- EML vs CHRS Comparison
EML vs CHRS Comparison
Compare EML & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EML
- CHRS
- Stock Information
- Founded
- EML 1858
- CHRS 2010
- Country
- EML United States
- CHRS United States
- Employees
- EML N/A
- CHRS N/A
- Industry
- EML Industrial Machinery/Components
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EML Consumer Discretionary
- CHRS Health Care
- Exchange
- EML Nasdaq
- CHRS Nasdaq
- Market Cap
- EML 191.3M
- CHRS 191.3M
- IPO Year
- EML N/A
- CHRS 2014
- Fundamental
- Price
- EML $28.15
- CHRS $1.32
- Analyst Decision
- EML
- CHRS Strong Buy
- Analyst Count
- EML 0
- CHRS 4
- Target Price
- EML N/A
- CHRS $5.38
- AVG Volume (30 Days)
- EML 10.1K
- CHRS 2.0M
- Earning Date
- EML 03-11-2025
- CHRS 03-12-2025
- Dividend Yield
- EML 1.59%
- CHRS N/A
- EPS Growth
- EML N/A
- CHRS N/A
- EPS
- EML N/A
- CHRS N/A
- Revenue
- EML $284,461,286.00
- CHRS $304,340,000.00
- Revenue This Year
- EML N/A
- CHRS $2.47
- Revenue Next Year
- EML N/A
- CHRS N/A
- P/E Ratio
- EML $13.80
- CHRS N/A
- Revenue Growth
- EML 7.70
- CHRS 44.19
- 52 Week Low
- EML $22.63
- CHRS $0.66
- 52 Week High
- EML $35.78
- CHRS $2.87
- Technical
- Relative Strength Index (RSI)
- EML 54.79
- CHRS 41.91
- Support Level
- EML $25.31
- CHRS $1.38
- Resistance Level
- EML $29.39
- CHRS $1.60
- Average True Range (ATR)
- EML 0.79
- CHRS 0.12
- MACD
- EML 0.29
- CHRS -0.03
- Stochastic Oscillator
- EML 69.61
- CHRS 1.10
About EML Eastern Company (The)
The Eastern Co manages industrial businesses that design, manufacture, and sell engineered solutions to industrial markets. The company manages the financial, operational, and strategic performance of its businesses to increase cash generation, operating earnings, and long-term shareholder value. It operates in the United States and Other Countries and generates the majority of its revenue from the United States.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.